Inicio / GLP-1 Vision Loss

Artículo 34 · Contingencia

GLP-1 Vision Loss

People who lost vision in one eye after taking Ozempic, Wegovy, Saxenda, Trulicity or another GLP-1 drug are suing the manufacturers over an eye stroke called NAION. European regulators added NAION to the semaglutide label in June 2025. The United States label still does not carry it. Jim Glaser Law reviews Massachusetts GLP-1 vision loss claims at no cost.

Última actualización

Primera llamada gratis (617) JIM-WINS Pregunte a la IA →

La respuesta corta

Lawsuits alleging that GLP-1 drugs caused non-arteritic anterior ischemic optic neuropathy, an eye stroke usually called NAION, are consolidated in their own federal multidistrict litigation, In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL No. 3163, created by the Judicial Panel on Multidistrict Litigation on December 15, 2025 and assigned to Judge Karen S. Marston in the Eastern District of Pennsylvania. That is a separate MDL from the gastrointestinal GLP-1 litigation, MDL No. 3094, before the same judge. The JPML transfer order names Ozempic, Wegovy, Saxenda and Trulicity, so the litigation already reaches liraglutide and dulaglutide and is not limited to semaglutide. Plaintiffs bring failure to warn, design defect and breach of warranty claims against Novo Nordisk and Eli Lilly. The central allegation is a warning gap that can be checked in the documents themselves: the European Medicines Agency concluded on June 6, 2025 that NAION is a very rare side effect of semaglutide and required it on European product information, while the United States prescribing information reviewed for this page does not mention NAION, ischemic optic neuropathy or optic neuropathy anywhere in its 34 pages. The Massachusetts theory rests on the implied warranty of merchantability under M.G.L. c. 106 sec. 2-314, the consumer-protection statute at c. 93A, and the three-year deadline in c. 260 sec. 2A, where the discovery rule matters because most patients are never told the drug is a suspect. These matters are accepted on contingency, meaning no attorney's fee unless and until the matter resolves with a recovery to the client; case-related costs and expenses are addressed in the written fee agreement. Call Jim Glaser Law at (617) JIM-WINS. The line is answered 24 hours a day. The first telephone consultation is offered without charge.

Obtenga ayuda ahora

Hable con la firma sobre su asunto de glp-1 vision loss

La línea se contesta las 24 horas del día. La primera consulta telefónica se ofrece sin costo. O envíe sus datos y la firma se comunica dentro de un día hábil.

Llamada gratis primero(617) JIM-WINS
O envíe sus datos

¿Qué cubre la ley de glp-1 vision loss en Massachusetts?

People who lost vision in one eye after taking Ozempic, Wegovy, Saxenda, Trulicity or another GLP-1 drug are suing the manufacturers over an eye stroke called NAION. European regulators added NAION to the semaglutide label in June 2025. The United States label still does not carry it. Jim Glaser Law reviews Massachusetts GLP-1 vision loss claims at no cost.

Lawsuits alleging that GLP-1 drugs caused non-arteritic anterior ischemic optic neuropathy, an eye stroke usually called NAION, are consolidated in their own federal multidistrict litigation, In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL No. 3163, created by the Judicial Panel on Multidistrict Litigation on December 15, 2025 and assigned to Judge Karen S. Marston in the Eastern District of Pennsylvania. That is a separate MDL from the gastrointestinal GLP-1 litigation, MDL No. 3094, before the same judge. The JPML transfer order names Ozempic, Wegovy, Saxenda and Trulicity, so the litigation already reaches liraglutide and dulaglutide and is not limited to semaglutide. Plaintiffs bring failure to warn, design defect and breach of warranty claims against Novo Nordisk and Eli Lilly. The central allegation is a warning gap that can be checked in the documents themselves: the European Medicines Agency concluded on June 6, 2025 that NAION is a very rare side effect of semaglutide and required it on European product information, while the United States prescribing information reviewed for this page does not mention NAION, ischemic optic neuropathy or optic neuropathy anywhere in its 34 pages. The Massachusetts theory rests on the implied warranty of merchantability under M.G.L. c. 106 sec. 2-314, the consumer-protection statute at c. 93A, and the three-year deadline in c. 260 sec. 2A, where the discovery rule matters because most patients are never told the drug is a suspect. These matters are accepted on contingency, meaning no attorney's fee unless and until the matter resolves with a recovery to the client; case-related costs and expenses are addressed in the written fee agreement. Call Jim Glaser Law at (617) JIM-WINS. The line is answered 24 hours a day. The first telephone consultation is offered without charge.

Casos de este tipo han sido manejados por Jim Glaser Law en Massachusetts desde 1995. La primera consulta telefónica se ofrece sin costo. Para asuntos que Jim Glaser Law acepta en contingencia, no se debe ningún honorario de abogado a menos que y hasta que el asunto se resuelva con una recuperación al cliente; los costos y gastos relacionados con el caso se abordan en el acuerdo escrito de honorarios.

Ciudades que cubrimos

Cada ciudad de Massachusetts a continuación tiene un sub-artículo dedicado que localiza la regla de glp-1 vision loss y nombra las cortes relevantes para esa jurisdicción.

Preguntas frecuentes

  • ¿Cuál es el plazo para presentar un reclamo de glp-1 vision loss en Massachusetts?

    La mayoría de los reclamos civiles de Massachusetts de este tipo están sujetos a un plazo de prescripción de tres años bajo M.G.L. c. 260 § 2A desde la fecha en que se acumula la causa de acción. Algunos asuntos tienen plazos más cortos. Llame al (617) JIM-WINS para orientación específica a sus hechos.

  • ¿Jim Glaser Law ofrece consulta gratis?

    Sí. La primera consulta telefónica se ofrece sin costo. Llame al (617) JIM-WINS, la línea se contesta las 24 horas del día, los 7 días de la semana.

  • ¿Cómo cobra Jim Glaser Law por la representación de glp-1 vision loss?

    Los asuntos de GLP-1 Vision Loss se aceptan por contingencia: ningún honorario de abogado a menos que y hasta que el asunto se resuelva con una recuperación al cliente; los costos y gastos relacionados con el caso se abordan en el acuerdo escrito de honorarios.

  • ¿Dónde está ubicada Jim Glaser Law?

    La oficina principal está en 77 Pond Street, Sharon, Massachusetts 02067. La firma acepta casos de glp-1 vision loss en todo el estado. La mayoría de las consultas se manejan por teléfono o video.

  • ¿Hay servicio en español?

    La extensión de IA en /es/ask responde inmediatamente en español. El seguimiento por un abogado puede ocurrir en inglés o coordinarse con un abogado o intérprete bilingüe según la disponibilidad. Llame al (617) JIM-WINS.

¿Listo para el siguiente paso?

Este artículo constituye información legal, no asesoramiento legal. Los resultados pasados no garantizan resultados futuros. Publicidad de abogados bajo Mass. R. Prof. C. 7.1 a 7.5. Abogado responsable: Jim Glaser, Massachusetts.

Jim Glaser Law

Solicitar una llamada

Deje un teléfono o correo electrónico. El bufete se comunicará dentro de un día hábil. Nada aquí crea una relación abogado-cliente.

O llame ahora (617) JIM-WINS
Llamar (617) JIM-WINS Obtener ayuda